![](https://www.inotrem.com/wp-content/uploads/2021/06/anti-TREM-1-1.png)
Inotrem adds a new strategic asset to its immunotherapy anti-TREM-1 drug pipeline
Paris. June 23, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that it has